Lineweaver Wealth Advisors LLC Increases Position in Johnson & Johnson $JNJ

Key Points

• Lineweaver Wealth Advisors LLC increased its stake in Johnson & Johnson by 13.8% during the 2nd quarter, now holding 24,161 shares valued at approximately $3.69 million.
• Several hedge funds, including Vanguard Group and Bank of New York Mellon Corp, have also boosted their holdings in Johnson & Johnson, indicating strong institutional interest in the stock.
• Analysts have raised their price targets for Johnson & Johnson, with Citigroup and JPMorgan both setting targets at $200, while the stock currently holds a "Moderate Buy" rating with an average target price of $177.87.

Lineweaver Wealth Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,161 shares of the company's stock after purchasing an additional 2,926 shares during the period. Lineweaver Wealth Advisors LLC's holdings in Johnson & Johnson were worth $3,691,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC raised its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter valued at approximately $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Finally, Capital A Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $50,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 16th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Guggenheim reissued a "neutral" rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $177.87.

Johnson & Johnson Trading Up 1.0%

Shares of JNJ stock traded up $1.81 during mid-day trading on Friday, reaching $175.97. The stock had a trading volume of 25,617,065 shares, compared to its average volume of 6,995,150. The stock's 50-day moving average price is $172.80 and its two-hundred day moving average price is $161.67. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The firm has a market capitalization of $423.80 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.